促甲状腺激素、甲状腺球蛋白抗体对甲状腺结节良、恶性的评估

目的 分析促甲状腺激素和甲状腺球蛋白抗体对甲状腺结节良恶性的判断价值.方法 整群选取2012年1月—2015年3月经该院病理切片确诊的23例甲状腺恶性结节(恶性组)、25例甲状腺良性结节(良性组)及健康志愿者20例(对照组)作为研究对象. 记录和比较所有研究对象进行促甲状腺激素、甲状腺球蛋白抗体水平及异常比例. 结果 恶性组促甲状腺激素[(3.46±1.23)vs(2.35±1.08)]和甲状腺球蛋白抗体[(135.43±49.46)vs(83.62±28.69)]水平高于良性组,差异有统计学意义(P<0.05);但两组2指标定性比较差异无统计学意义(P>0.05). 结论 促甲状腺激素、甲状腺球蛋白抗体在甲状腺良、恶性结节的确存在差异,但不宜采用人体正常参考值作为分别甲状腺良、恶性结节的标准.

Evaluation of thyroid stimulating hormone and thyroid globulin antibody on the benign and malignant thyroid nodules

Objective To analyze the value of thyroid stimulating hormone and thyroid globulin antibody in the judgment of benign and malignant thyroid nodules. Methods 23 cases of thyroid malignant nodules (malignant group), 25 cases of be-nign thyroid nodules (benign group) and 20 healthy volunteers (control group) were used as the research object in the 3 cas-es of 2015 to January 2012. Recording and comparing all of the study subjects to promote thyroid hormone, thyroid globulin antibody levels and abnormal proportion. Results tThe levels of thyroid stimulating hormone [(3.46±1.23)vs (2.35±1.08)] and thyroid globulin[(135.43±49.46)vs(83.62±28.69)] were higher in malignant group than in benign group, but the differ-ence between the 2 groups was not significantly different in the two groups. Conclusion Thyroid stimulating hormone, thy-roid globulin antibody in thyroid nodules, malignant nodules indeed exist differences, but it is not suitable for the use of human normal reference value as a standard of thyroid benign and malignant nodules.